HOOKIPA Pharma Statistics
Total Valuation
HOOKIPA Pharma has a market cap or net worth of $13.92 million. The enterprise value is -$24.01 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HOOKIPA Pharma has 12.54 million shares outstanding. The number of shares has increased by 32.65% in one year.
| Current Share Class | 9.66M |
| Shares Outstanding | 12.54M |
| Shares Change (YoY) | +32.65% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 26.56% |
| Float | 9.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| Forward PS | n/a |
| PB Ratio | 0.29 |
| P/TBV Ratio | 0.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.27, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.27 |
| Quick Ratio | 2.57 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22,393.50 |
Financial Efficiency
Return on equity (ROE) is -61.68% and return on invested capital (ROIC) is -37.70%.
| Return on Equity (ROE) | -61.68% |
| Return on Assets (ROA) | -22.96% |
| Return on Invested Capital (ROIC) | -37.70% |
| Return on Capital Employed (ROCE) | -77.36% |
| Revenue Per Employee | $505,126 |
| Profits Per Employee | -$500,034 |
| Employee Count | 87 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -106,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.62% in the last 52 weeks. The beta is 0.70, so HOOKIPA Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -83.62% |
| 50-Day Moving Average | 1.61 |
| 200-Day Moving Average | 3.62 |
| Relative Strength Index (RSI) | 33.67 |
| Average Volume (20 Days) | 49,217 |
Short Selling Information
The latest short interest is 70,638, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 70,638 |
| Short Previous Month | 66,198 |
| Short % of Shares Out | 0.56% |
| Short % of Float | 0.74% |
| Short Ratio (days to cover) | 1.03 |
Income Statement
In the last 12 months, HOOKIPA Pharma had revenue of $43.95 million and -$43.50 million in losses. Loss per share was -$3.47.
| Revenue | 43.95M |
| Gross Profit | -23.19M |
| Operating Income | -44.79M |
| Pretax Income | -48.43M |
| Net Income | -43.50M |
| EBITDA | -42.03M |
| EBIT | -44.79M |
| Loss Per Share | -$3.47 |
Full Income StatementBalance Sheet
The company has $39.68 million in cash and $875,000 in debt, giving a net cash position of $38.81 million or $3.09 per share.
| Cash & Cash Equivalents | 39.68M |
| Total Debt | 875,000 |
| Net Cash | 38.81M |
| Net Cash Per Share | $3.09 |
| Equity (Book Value) | 51.21M |
| Book Value Per Share | 4.08 |
| Working Capital | 56.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$76.98 million and capital expenditures -$194,000, giving a free cash flow of -$77.17 million.
| Operating Cash Flow | -76.98M |
| Capital Expenditures | -194,000 |
| Free Cash Flow | -77.17M |
| FCF Per Share | -$6.15 |
Full Cash Flow StatementMargins
Gross margin is -52.76%, with operating and profit margins of -101.91% and -98.99%.
| Gross Margin | -52.76% |
| Operating Margin | -101.91% |
| Pretax Margin | -99.23% |
| Profit Margin | -98.99% |
| EBITDA Margin | -95.65% |
| EBIT Margin | -101.91% |
| FCF Margin | n/a |
Dividends & Yields
HOOKIPA Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.65% |
| Shareholder Yield | n/a |
| Earnings Yield | -293.92% |
| FCF Yield | -521.39% |
Analyst Forecast
The average price target for HOOKIPA Pharma is $10.67, which is 861.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.67 |
| Price Target Difference | 861.26% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | -14.23% |
| EPS Growth Forecast (5Y) | -12.00% |
Stock ForecastsStock Splits
The last stock split was on July 10, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Jul 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
HOOKIPA Pharma has an Altman Z-Score of -6.04 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.04 |
| Piotroski F-Score | 2 |